<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01814410</url>
  </required_header>
  <id_info>
    <org_study_id>1209010841</org_study_id>
    <nct_id>NCT01814410</nct_id>
  </id_info>
  <brief_title>Interactive Effects of IV Ethanol and IV Nicotine</brief_title>
  <official_title>A Laboratory Study on the Interactive Effects of IV Ethanol and IV Nicotine on Subjective Effects and Cognition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>South Central VA Mental Illness Research, Education &amp; Clinical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are mixed reports on nicotine's effects on ethanol-induced impairment in cognitive
      performance and behavior in humans. The main objective of this study is to characterize the
      interactive effects of acute intravenous (IV) ethanol and nicotine administration on
      cognition and behavior in healthy smokers. The general hypothesis is that nicotine will
      attenuate the negative effects of ethanol on cognition and subjective stimulant/sedative
      effects of ethanol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biphasic Alcohol Effects Scale (BAES)</measure>
    <time_frame>2 minutes</time_frame>
    <description>A 14-item scale with 7 items designed to assess stimulant effects associated with the ascending limb of ethanol intoxication and 7 items developed to measure sedative effects associated with the descending limb of ethanol intoxication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scales of Mood States</measure>
    <time_frame>1 minute</time_frame>
    <description>The following items will be assessed: high, depressed, anxious, drowsy, irritable, tired, sad, angry, nervous, nauseous, blurred vision, flushed, headache, lightheaded, dizzy, sweating, abdominal discomfort and tingling .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QSU-Brief</measure>
    <time_frame>2 minutes</time_frame>
    <description>A measure of smoking urges reflecting not only intent and desire to smoke, and anticipation of pleasure from smoking, but also anticipation of relief from negative affect and nicotine withdrawal, and urgent and overwhelming desire to smoke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digit Symbol Substitution Task</measure>
    <time_frame>2 minutes</time_frame>
    <description>A test of psychomotor performance, which measures motor persistence, sustained attention, response speed and visuomotor coordination.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>intravenous ethanol placebo and nicotine infusions</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravenous ethanol 40% and nicotine infusions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravenous ethanol 100% and nicotine infusions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous ethanol placebo plus nicotine infusions</intervention_name>
    <description>nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg</description>
    <arm_group_label>intravenous ethanol placebo and nicotine infusions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous ethanol 40mg% plus nicotine infusions</intervention_name>
    <description>nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg</description>
    <arm_group_label>intravenous ethanol 40% and nicotine infusions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous ethanol 100mg% plus nicotine infusions</intervention_name>
    <description>nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg</description>
    <arm_group_label>intravenous ethanol 100% and nicotine infusions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female;

          2. between the ages of 21 and 50 years;

          3. medically and neurologically healthy on the basis of history, physical examination,
             EKG, screening laboratories

          4. history of smoking daily for the past 12 months, at least 5 cigarettes daily; not
             seeking treatment for nicotine dependence

          5. social drinkers no maximum level of alcohol consumption will be defined a priori but
             individuals who met current DSM -IV criteria for alcohol dependence (abuse will be
             allowed) will be excluded from the study.

        Exclusion Criteria:

          1. history of major medical illnesses that the physician investigator deems as
             contraindicated for the patient to be in the study;

          2. regular use of psychotropic medication (antidepressants, antipsychotics, or
             anxiolytics) and recent psychiatric diagnosis and treatment for Axis I disorders
             including major depression, bipolar affective disorder, schizophrenia or panic
             disorder;

          3. current abuse of any recreational or prescription drugs (except alcohol);

          4. alcohol na√Øve.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Ralevski, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Haven VA Hospital</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2013</study_first_submitted>
  <study_first_submitted_qc>March 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2013</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intravenous Ethanol</keyword>
  <keyword>Intravenous Nicotine</keyword>
  <keyword>Interactive effects</keyword>
  <keyword>cognition</keyword>
  <keyword>subjective effects</keyword>
  <keyword>healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

